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ABSTRACT
Limited number of experimental and clinical studies showed rapid tumor regrowth after bevacizumab cessation in advanced colorectal 
cancer. We retrospectively evaluated rapid regrowth phenomenon in 105 patients those who were treated with the predefined number 
of chemotherapy cycles and grouped according to whether the chemotherapy regimen in the first line setting included bevacizumab 
(CT-Bev arm) or not (CT arm). Median age was 55 years old. Median overall and progression free survival times were 27 and 11 
months, respectively. Rapid progression rates were 42% and 40% in CT arm and CT-Bev arm without no statistically significant differ-
ence (p= 0.84). In CT arm, significantly more patients with stable disease (SD) progressed rapidly compared to patients with complete 
(CR) or partial response (PR) (53% vs. 27%, p= 0.04). This result was also similar in CT-Bev arm (48% vs. 30%, p= 0.27) but could 
not reach to the significant p-value. Overall survival 2, the time from the end of last dose of chemotherapy +/- bevacizumab to death, 
was significantly shorter in both CT and CT-Bev arms for patients who showed SD compared to CR or PR (15 vs 38 months) (p< 
0.001).Current study supports that withdrawal of bevacizumab after predefined treatment cycles may not have any adverse effect 
on patients’ outcome of advanced CRC. This result is particularly acceptable for the patients who show CR or PR to the treatment. 
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ÖZET
İleri Evre Kolorektal Kanserli Hastalarda Alevlenme Fenomeni: Önceden Belirlenmiş Sayida Verilen Bevasizumabin 
Kesilmesi Sağkalimi Olumsuz Etkilemeyebilir
Sınırlı sayıda deneysel ve klinik çalışmada ileri evre kolorektal kanserli hastada bevasizumabın kesilmesinin hızlı tümör büyümesine 
neden olduğu gösterilmiştir. Hızlı tümör büyümesi fenomenini birinci basamakta daha önceden belirlenmiş sayıda kemoterapi alan ve 
aldıkları kemoterapi rejiminin bevasizumab içerip içermemesine göre 2 gruba ayrılan (KT-Bev veya KT) 105 kolorektal kanserli hastada 
değerlendirdik. Ortanca yaş 55 idi. Ortanca toplam ve progresyonsuz sağkalım süresi sırasıyla 27 ve 11 aydı. Hızlı progresyon oranı 
KT ve KT-Bev kolunda sırası ile %42 ve %40 idi ve aralarında istatistiksel fark yoktu (p= 0.84). KT kolunda stabil hastalığı (SH) olanlar 
tam (TY) veya kısmi (KY) yanıt gösterenlere göre anlamlı olarak hızlı progresyon gösterdiler (%53 vs. %27, p= 0.04). Bu sonuç KT-Bev 
kolunda benzer olmakla birlikte istatistiksel anlamlılığa ulaşmadı (%48 vs.%30, p= 0.27). Son kemoterapi +/- bevasizumab dozundan 
ölüme kadar geçen süre olarak tanımlanan toplam sağkalım 2 süesi (TS2) SD’de TY veya KY olanlara göre daha kısa idi (15 vs 38 ay: 
p<0,001). Bu çalışma daha önceden belirlenmiş sayıda verilmiş olan bevasizumabın kesilmesinin ileri evre kolorektal kanserli hastalarda 
sağkalımı olumsuz etkilemeyebileceğini desteklemektedir. Bu özellikle tedaviye TY veya KY gösterenler için geçerlidir.
Anahtar Kelimeler: Alevlenme fenomeni, Kolorektal kanser, Bevasizumab kesilmesi, Kemoterapi, Rebound progresyon. 
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INTRODUCTION 
Angiogenesis, one of the ten cancer hallmarks, is 
necessary for the development of tumor beyond 
the certain volume, facilitates invasion, and metas-
tases.1 VEGF (vascular endothelial growth factor) 
is a potent growth factor that has a central role in 
regulating tumor angiogenesis.2,3 It increases en-
dothelial cell spurring, help the formation of the 
new vascular vessel, with a higher concentration 
around the tumor, leads to newly forming vessels 
to tumor tissue.3,4 Bevacizumab, a monoclonal 
antibody targeting VEGF molecule, significantly 
decrease VEGF concentration in the tumor micro-
environment and exerts the anti-tumor effect by 
disturbing tumor nourishment. VEGF receptors are 
highly expressed in colon cancer. There is strong 
evidence supported by randomized phase studies 
that bevacizumab shows an improvement in re-
sponse rate and survival rates in advanced colorec-
tal cancer (CRC).5-8 Although, the positive impact 
of bevacizumab was on response parameters, the 
main effect of bevacizumab is cytostatic rather that 
cytotoxic. This comes with the concern of rapid 
tumor regrowth after discontinuation of bevaci-
zumab. 
The experimental study reported by Mancuso et.al. 
showed that interruption of anti-VEGF therapy re-
sulted with fully tumor revascularization through 
the surviving pericytes and empty sleeves of vas-
cular basement membrane in mice model in sev-
en days.9 Beyond this experimental study, there 
is a small clinical study by Cacheux et.al. which 
showed rapid tumor regrowth occurred between 
the second and third month after cessation of bev-
acizumab.10 As far as we know there is no study 
addressing the impact of stopping bevacizumab 
on outcomes of advanced colorectal cancer for pa-
tients who do not progress on this therapy. 
To evaluate this, we retrospectively analyzed non-
progressive advanced CRC patients treated with 
predefined cycles of chemotherapy with or without 
bevacizumab to show the effects of bevacizumab 
cessation on rapid regrowth phenomenon. 
PATIENTS AND METHOD
Medical charts of 400 advanced colorectal carci-
noma patients followed by the Department of Med-
ical Oncology at Baskent University and Ankara 
Numune Research and Training Hospital between 
2001 and 2010 were reviewed retrospectively. Due 
to local reimbursement issues, advanced CRC 
patients could be treated with bevacizumab plus 
chemotherapy in the first line setting during this 
period. 105 patients were suitable for the aim of 
the study. All patients were treated with chemo-
therapy plus bevacizumab or chemotherapy; at 
least, for two months with the proven clinical ben-
efit (CR+PR+SD) according to RECIST 1.1. The 
patients with treatment related unmanageable drug 
toxicity or intolerance were excluded, but dose 
reduction permitted according to CTCAE IV. All 
patients had histologically confirmed stage IV co-
lon or rectum adenocarcinoma. Demographic and 
clinical characteristics of patients including age, 
localization of primary tumor (rectum vs colon), 
sequence of metastatic disease (metachronous vs 
synchronous metastasis), grade of tumor, type 
of chemotherapy in metastatic setting and prior 
adjuvant chemotherapy were recorded. Patients 
grouped according to whether the chemotherapy 
regimen administered in the first line setting in-
cluded bevacizumab (CT-Bev arm) or not (CT 
arm).
Chemotherapy Regimens
In patients on CT-Bev arm, bevacizumab (5 mg/
kg, first dose over 90 minutes and after that over 30 
minutes if tolerated well ) was administered only 
combined with standard FOLFIRI regimen (leu-
covorin (LV) 400 mg/m2 as a 2-hour infusion fol-
lowed by irinotecan 180 mg/m2 given as a 90-min-
ute infusion and then 5 fluorouracil (5-FU) 400 
mg/m2 iv bolus followed by 5-FU 2400 mg/m2 ad-
ministered as a 46-hour infusion every two weeks) 
due to reimbursement issues. FOLFIRI plus beva-
cizumab was given as predefined number of cycles 
(minimum four cycles and up to maximum 12 cy-
cles). The remaining patients were treated with ox-
aliplatin based regimens which consisted of oxali-
platin (100 mg/m2 and 85 mg/m2 given as a 2-hour 
infusion as FOLFOX-6 and modified FOLFOX-4 
respectively) plus 5-FU+LV as the same protocol 
that mentioned above or 5-FU plus LV alone or 
irinotecan combined with bolus 5-fluorouracil/leu-
covorin (Saltz regimen) or capecitabine as a single 
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agent according to the physician’s choice. Patients 
in CT arm were also given chemotherapy for pre-
defined number of cycles (minimum four cycles 
and up to maximum 12 cycles) not until progres-
sion. 
Statistical Analysis
All results were presented as rate for categorical 
values or mean and median for continuous vari-
ables. The primary objective of this study was to 
assess PFS 2 which is defined as the time from the 
last dose of bevacizumab (CT-Bev arm) or chemo-
therapy (CT arm) to the first documentation of pro-
gression or death. PFS 1 was defined as the time 
from the initiation of first line chemotherapy to 
the initial sign of progression or death. OS1 was 
calculated from the first dose of chemotherapy 
administration to death and OS2 defined as the 
time from the end of last dose of chemotherapy 
+/- bevacizumab to death. In this study, rapid pro-
gression was defined as progression within three 
months after cessation of chemotherapy or chemo-
therapy plus bevacizumab. Survival curves were 
estimated according to the Kaplan-Meier method 
and log-rank tests were used for univariate statisti-
cal comparisons. Adjusted hazard ratios and 95% 
confidence intervals (95% CIs) were used for esti-
Table 1. Baseline characteristics of patients 
Characteristics All patients (n= 105) CT (n=62) CT-Bev (n= 43) 
 
Age, years
   Median (Range) 55 (28-81)
   Mean  58 50 p< 0.01
Sex     p= 0.06
   Male 65 (62%) 43 (69%) 22 (51%)
   Female 40 (38%) 19 (31%) 21 (49%) 
Localization of primary tumor    p= 0.69
   Rectum 52 (49%) 31 (50%) 21 (49%)
   Colon 53 (51%) 31 (50%) 22 (51%) 
Grade    p= 0.24
    1 40 (38%) 26 (42%) 14 (32%)
    2 37 (35%) 17 (27%) 20 (47%)
    3 15 (14%) 10 (16%) 5   (12%)
    Unknown 13 (12%) 9   (15%) 4   (9%) 
Sequence of metastatic disease    p= 0.053
   Synchronous 46 (44%) 32 (52%) 14 (33%)
   Metachronous 59 (56%) 30 (48%) 29 (67%) 
Adjuvant chemotherapy    p< 0.01
   No 61 (58%) 44 (71%) 17 (40%)
   Yes 44 (42%) 18 (29%) 26 (60%) 
First line chemotherapy
   FOLFOX 53
   FOLFIRI-Bev.  43
   Capecitabine 4
   Fu-Fa 1
   Saltz 4   
Best response to first line chemotherapy    p= 0.74
CR 16 (15%) 10 (16%) 6   (14%)
PR 30 (29%) 16 (26%) 14 (33%)
SD 59 (56%) 36 (58%) 23 (53%) 
Abbreviations:  FOLFOX, oxaliplatin plus fluorouracil/leucovorin; FOLFIRI, , irinotecan plus fluorouracil/leucovorin; Fu-Fa, fluoroura-
cil/leucovorin; Bev, bevacizumab; CR, complete response; PR, partial response; SD, stable disease.
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mation. All data were analyzed using SPSS version 
15.0 (SPSS Inc., Chicago, IL) and a p value of < 
0.05 was considered statistically significant.
RESULTS 
A total of 105 patients, 38% (n= 40) were female 
and median age was 55 years old (range 28-81). 
Some of the patient and disease characteristics are 
summarized in Table 1. Rate of the primary tumor 
localization and grades did not show statistically 
significant difference between CT arm and CT-
Bev arm (p> 0.05 for both). However, statistically 
analyses showed significant difference between 
two groups with regard to adjuvant chemotherapy 
(29% vs 60% of the patients were given adjuvant 
chemotherapy in CT arm and CT-Bev arm respec-
tively) and age (58 in CT arm vs 50 years old in 
CT-Bev arm) with p values of p< 0.001 and p< 
0.001 respectively. FOLFIRI was the only regimen 
combined with bevacizumab and FOLFOX was 
the main regimen in CT arm (85% of patients). 
The median PFS2 was 5.0 months (95% CI, 3.5-
6.4) for CT arm and 5.0 months (95% CI, 3.6-6.3) 
for CT-Bev arm (p= 0.33) (Figure 1). Univariate 
analyses failed to show statistically significant ef-
fect of primary tumor localization, tumor grade, the 
sequence of metastatic disease, ECOG PS, sex and 
administration of adjuvant chemotherapy on PFS2. 
PFS1 was 10.0 (95% CI, 8.9-11.0) and 11.0 (95% 
CI, 10.0-12.7) months for the CT arm and CT-Bev 
arm, respectively (p= 0.24) (Table2). Univariate 
analyses failed to show the statistically significant 
effect of primary tumor localization, tumor grade, 
sequence of metastatic disease, ECOG PS, sex and 
administration of adjuvant chemotherapy on PFS1.
The median duration of OS1 for the entire cohort 
was 27.0 months (95% CI, 21.6-32.3). Kaplan-
Meier curve for OS1 is shown in Figure 2. The 
median OS1 was found as 27 and 28 months in CT 
arm and CT-Bev arm, respectively (p> 0.05). 
Table 2. Definitions and median times of PFS1, PFS2, OS1 and OS2 according to the treatment groups. 
                                                                                       OS
                                               PFS
                                                                                  PFS2
                                                                                                                               OS2 
Survival (months) All patients  CT CT-Bev  
mPFS1 11.0 (10.0-11.9) 10.0 (8.9-11.0) 11.0 (10.0-12.7) p= 0.24
mPFS2 5.0 (3.99-6.00) 5.0 (3.5-6.4) 5.0 (3.6-6.3) p= 0.33
mOS1 27.0 (21.6-32.3) 27.0 (19.6-34.3) 28.0 (21.6-34.3) p= 0.54
mOS2 21.0 (16.1-25.8) 21.0 (13.6-28.3) 23.0 (16.9-29.0) p= 0.58
Figure 1. Kaplan-Meier estimate of progression free survival 2 
according to treatment groups
Starting
Chemotherapy±
Bevacizumab
End of first line 
Chemotherapy± 
Bevacizumab
Progression Death
CT
CT-Bev
CT-censored
CT-Bev-censored
p= 0.33 (log-rank  
      test)
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The median OS2 was found 21.0 months for all pa-
tients (95% CI, 16.1-25.8) and was similar in CT 
arm and CT-Bev arm as shown in Figure 3. How-
ever, for patients with SD OS2 was significantly 
lower compared to patients who had CR or PR 
(15.0 vs 38.0 months) (p< 0.001) (Figure 4)
 Number of patients with rapid progression were 
found in 26 (42%) in CT arm and 17 (40%) in CT-
Bev arm, there was no statistically significant dif-
ference (p= 0.84).
According to the best first line chemotherapy re-
sponse, number of patients with CR, PR and, SD 
were found as 10 (16%) vs. 6 (14%), 16 (26%) vs. 
14 (33%) and, 36 (57%) vs 23 (53%) for patients 
in CT arm and CT-Bev arm, respectively (p> 0.05 
for all).
In CT arm, significantly more patients with SD 
(19 of 36 patients) progressed rapidly compared 
to patients with CR or PR (7 of 26 patients) (53% 
vs. 27%) (p= 0.04). In CT-Bev arm, although not 
reached to threshold of statistically significant 
value, rapid progression rate was also higher in 
patients with SD (48% vs. 30%) (p= 0.23) when 
compared to patients with CR and PR. 
DISCUSSION
The survival of advanced CRC has improved nota-
bly in the recent years by the contribution of novel 
biological drugs such as anti-epidermal growth 
factor and anti-VEGF antibodies to conventional 
chemotherapy. However, there is still a debate on 
the optimal combination and duration of chemo-
therapeutics and biological agents. The incorpo-
ration of anti-VEGF treatment into 5-fluorouracil 
based cytotoxic regimens is an option in the first 
and second line treatment for advanced CRC. Con-
tinuous administration of bevacizumab until pro-
gression or unacceptable toxicity is recommended 
by well accepted international guidelines.11-13 How-
ever, there are some significant issues; the first is 
the high cost especially in continuous administra-
Figure 4. Kaplan-Meier estimate of overall survival 2 according 
to chemotherapy responses
Figure 3. Kaplan-Meier estimate of overall survival 2 according 
to treatment groups
Figure 2. Kaplan-Meier estimate of overall survival
CT
CT-Bev
CT-censored
CT-Bev-censored
p= 0.54 (log-rank  
      test)
CT
CT-Bev
CT-censored
CT-Bev-censored
p= 0.58 (log-rank  
      test)
SD
CR+PR
SD-censored
CR+PR-censored
p< 0.001 (log-rank 
test)
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tion. The second is accelerated tumor progression 
after cessation of the anti-VEGF, bevacizumab in 
particular, which is endorsed by several preclini-
cal and observational studies.9,10,14 The third issue 
is evidence supporting the continuation of beva-
cizumab beyond progression in the second-line.13 
Therefore, defining a particular group of patients 
who can safely discontinue bevacizumab after 
proven tumor response is necessary and may help 
to solve these issues. To the best of our knowledge, 
this is the first study challenging cessation of beva-
cizumab after predefined treatment cycles in ad-
vanced CRC. 
To criticize, we mainly evaluated PFS2 and pro-
gression within three months of bevacizumab and/
or chemotherapy. We suppose that these two pa-
rameters were of particular importance in the eval-
uation of the rapid progression after bevacizumab 
therapy since they were not affected by the data of 
subsequent treatments. Our study results showed 
that median PFS2 was similar for both CT and CT-
Bev arms. Likewise, the rate of rapidly progressed 
patients was not different in two groups (nearly 
40%). But, we found statistically significant cor-
relation between OS2, type of response, and rapid 
progression rate. 
Statistical analysis failed to show significant dif-
ference between CT and CT-Bev arms with regard 
to OS1 and OS2. Discontinuation of bevacizumab 
was not associated with decreased PFS or rapid 
tumor progression in advanced CRC patients. Al-
though, OS1 and OS2 were not reduced in the sub-
group of patients who had rapid progression, thera-
pies in second and third line setting might explain 
this. Response to first-line chemotherapy showed 
the significant relation with primary outcomes 
(rapid progression rate and OS2) of this study. 
Rapid progression rate in CT arm was significantly 
higher in patients who showed SD compared to 
CR or PR, even though the higher rate of rapidly 
progressed patients in CT-Bev arm was not statisti-
cally significant.
OS2 in CT arm and CT-Bev arm was significantly 
shorter in patients who showed SD compared to CR 
or PR. Reduced survival rate of patients with SD 
was independent of discontinuation bevacizumab 
underlines the relevance of treatment response in 
advanced CRC. 
There are at least two more studies in the litera-
ture which evaluated the effect of bevacizumab 
cessation in non-progressed advanced cancer pa-
tients. Miles et al. retrospectively evaluated five 
randomized, placebo-controlled phase III studies 
(colorectal, breast, renal and pancreatic cancer) 
to investigate whether premature discontinuation 
of bevacizumab was associated with accelerated 
tumor progression. The final analysis of these five 
trials showed that time from discontinuation of 
treatment as a result of adverse events to death was 
similar for bevacizumab and placebo groups. In-
terestingly, PFS2 (5 months) in our patients were 
comparable to that reported in NO 16966 study 
(4.5 months for XELOX/FOLFOX plus bevaci-
zumab group) which included data of colorectal 
cancer patients for this pooled analysis.15 
Similar conclusions were drawn from the retro-
spective study reported by Anderson et al. in glio-
blastoma multiforme patients who discontinued 
bevacizumab for reasons other than tumor pro-
gression and received bevacizumab for at least 6 
months.16 
The potential rebound effect of bevacizumab was 
also addressed in the adjuvant colon cancer setting. 
The National Surgical Adjuvant Breast and Bowel 
Project C-08 trial was designed to assess the value 
of adding bevacizumab to modified FOLFOX 6 in 
stage II and III colon cancer. In this trial, number of 
patients who experienced recurrence and survival 
of patients after recurrence did not differ in the 
bevacizumab and the control arms.17
The limitations of our study were retrospective 
design in limited number patients, some degree 
of heterogeneity between CT arm and -Bev about 
patient characteristics, and absence of RAS muta-
tional analysis. The rate of patients with previous 
adjuvant chemotherapy was higher in CT-Bev arm, 
and higher age in CT arm at the time of diagnosis 
were the most important ones. Beside, RAS and 
BRAF mutational status might also influence the 
survival and response to chemotherapy.
In conclusion, the current study supports that in 
advanced CRC, cessation of bevacizumab after 
predefined treatment cycles may have no negative 
effect on patients’ outcome. This result is particu-
larly acceptable for the patients who show CR or 
PR to the treatment. 
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